Royalty Pharma to Present at Upcoming Investor Conferences
Royalty Pharma to Present at Upcoming Investor Conferences
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit . NEW YORK, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will participate in the following upcoming investor conferences during the month of December:
纽约，2024年11月27日(GLOBE NEWSWIRE) -- royalty pharma股份有限公司（纳斯达克：RPRX）今天宣布，将参加以下即将举行的投资者会议：
- 7th Annual Evercore ISI HealthCONx Conference on Tuesday, December 3 at 12:55 p.m. ET
- Citi's 2024 Global Healthcare Conference on Wednesday, December 4 at 1:45 p.m. ET
- 第七届Evercore ISI HealthCONx会议，将于东部时间12月3日星期二下午12:55举行。
- 花旗银行的2024年全球医疗保健会议，将于东部时间12月4日星期三下午1:45举行。
The webcasts will be accessible from Royalty Pharma's "Events" page at . Webcasts will also be archived for a minimum of thirty days.
网络研讨会将可从royalty pharma的“活动”页面访问。网络研讨会也将存档至少三十天。
About Royalty Pharma
关于Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 35 commercial products, including Vertex's Trikafta, GSK's Trelegy, Roche's Evrysdi, Johnson & Johnson's Tremfya, Biogen's Tysabri and Spinraza, AbbVie and Johnson & Johnson's Imbruvica, Astellas and Pfizer's Xtandi, Novartis' Promacta, Pfizer's Nurtec ODT and Gilead's Trodelvy, and 15 development-stage product candidates. For more information, visit .
成立于1996年，Royalty Pharma是生物制药版权的最大买家，也是生物制药行业创新的主要资助方，在学术机构、研究医院和非盈利组织、中小型生物技术公司和全球领先制药公司之间与创新者合作。Royalty Pharma已经建立起一系列版权组合，使其有资格根据行业领先治疗方案的销售额直接获得支付。Royalty Pharma通过直接和间接两种方式资助生物制药行业的创新 - 直接方式是与公司合作共同资助临床试验的后期阶段和新产品推出，以换取未来的版税，间接方式是从原始创新者那里收购现有的版税。Royalty Pharma目前的投资组合包括超过35种商业产品的版权，包括vertex的Trikafta，GSK的Trelegy，Roche的Evrysdi，强生的Tremfya，Biogen的Tysabri和Spinraza，艾伯维和强生的Imbruvica，爱力斯达和辉瑞的Xtandi，诺华的Promacta，辉瑞的Nurtec ODt和吉利德的Trodelvy，以及15个处于开发阶段的产品候选。欲获取更多信息，请访问。
Royalty Pharma Investor Relations and Communications
Royalty Pharma投资者关系与沟通
+1 (212) 883-6772
ir@royaltypharma.com
+1 (212) 883-6772
ir@royaltypharma.com
